US2015250790A1PendingUtilityA1

Topical formulation for a jak inhibitor

60
Assignee: INCYTE CORPPriority: May 21, 2010Filed: May 18, 2015Published: Sep 10, 2015
Est. expiryMay 21, 2030(~3.8 yrs left)· nominal 20-yr term from priority
Inventors:Bhavnish ParikhBhavesh ShahKrishnaswamy Yeleswaram
A61P 43/00A61P 37/02A61P 37/08A61P 17/02A61P 17/00A61P 17/04A61P 17/06A61K 9/0014A61K 47/06A61K 47/36A61K 31/519A61K 47/14A61K 9/107A61K 47/10A61K 47/24A61K 47/26A61K 47/18A61K 9/06A61K 9/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical formulation for topical skin application, comprising:
 an oil-in-water emulsion; and   a therapeutically effective amount of a therapeutic agent which is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.   
     
     
         2 . A pharmaceutical formulation according to  claim 1 , wherein the emulsion comprises water, an oil component, and an emulsifier component. 
     
     
         3 - 4 . (canceled) 
     
     
         5 . A pharmaceutical formulation according to  claim 2 , wherein the oil component is present in an amount of about 20% to about 27% by weight of the formulation. 
     
     
         6 . (canceled) 
     
     
         7 . A pharmaceutical formulation according to  claim 2 , wherein the oil component comprises one or more substances independently selected from white petrolatum, cetyl alcohol, stearyl alcohol, light mineral oil, medium chain triglycerides, and dimethicone. 
     
     
         8 . A pharmaceutical formulation according to  claim 2 , wherein the oil component comprises an occlusive agent component. 
     
     
         9 . (canceled) 
     
     
         10 . A pharmaceutical formulation according to  claim 8 , wherein the occlusive agent component is present in an amount of about 5% to about 10% by weight of the formulation. 
     
     
         11 . (canceled) 
     
     
         12 . A pharmaceutical formulation according to  claim 8 , wherein the occlusive agent component comprises white petrolatum. 
     
     
         13 . A pharmaceutical formulation according to  claim 2 , wherein the oil component comprises a stiffening agent component. 
     
     
         14 - 15 . (canceled) 
     
     
         16 . A pharmaceutical formulation according to  claim 13 , wherein the stiffening agent component is present in an amount of about 4% to about 7% by weight of said formulation. 
     
     
         17 - 18 . (canceled) 
     
     
         19 . A pharmaceutical formulation according to  claim 13 , wherein the stiffening agent component comprises one or more substances independently selected from C 16-18  fatty alcohols. 
     
     
         20 . (canceled) 
     
     
         21 . A pharmaceutical formulation according to  claim 2 , wherein the oil component comprises an emollient component. 
     
     
         22 . (canceled) 
     
     
         23 . A pharmaceutical formulation according to  claim 21 , wherein the emollient component is present in an amount of about 7% to about 13% by weight of the formulation. 
     
     
         24 - 25 . (canceled) 
     
     
         26 . A pharmaceutical formulation according to  claim 21 , wherein the emollient component comprises one or more substances independently selected from light mineral oil, medium chain triglycerides, and dimethicone. 
     
     
         27 - 28 . (canceled) 
     
     
         29 . A pharmaceutical formulation according to  claim 2 , wherein the water is present in an amount of about 45% to about 55% by weight of the formulation. 
     
     
         30 - 32 . (canceled) 
     
     
         33 . A pharmaceutical formulation according to  claim 2 , wherein the emulsifier component is present in an amount of about 4% to about 7% by weight of the formulation. 
     
     
         34 . (canceled) 
     
     
         35 . A pharmaceutical formulation according to  claim 2 , wherein the emulsifier component comprises one or more substances independently selected from glyceryl fatty esters and sorbitan fatty esters. 
     
     
         36 . (canceled) 
     
     
         37 . A pharmaceutical formulation according to  claim 2 , wherein said pharmaceutical formulation further comprises a stabilizing agent component. 
     
     
         38 - 39 . (canceled) 
     
     
         40 . A pharmaceutical formulation according to  claim 37 , wherein the stabilizing agent component is present in an amount of about 0.3 to about 0.5% by weight of the formulation. 
     
     
         41 . (canceled) 
     
     
         42 . A pharmaceutical formulation according to  claim 37 , wherein the stabilizing agent component comprises xanthan gum. 
     
     
         43 . A pharmaceutical formulation according to  claim 1 , wherein said pharmaceutical formulation further comprises a solvent component. 
     
     
         44 - 45 . (canceled) 
     
     
         46 . A pharmaceutical formulation according to  claim 43 , wherein the solvent component is present in an amount of about 20% to about 25% by weight of the formulation. 
     
     
         47 . A pharmaceutical formulation according to  claim 43 , wherein the solvent component comprises one or more substances independently selected from alkylene glycols and polyalkylene glycols. 
     
     
         48 . (canceled) 
     
     
         49 . A pharmaceutical formulation according to  claim 1 , wherein the therapeutic agent is present in an amount of about 0.5% to about 1.5% by weight of the formulation on a free base basis. 
     
     
         50 . A pharmaceutical formulation according to  claim 1 , wherein said therapeutic agent is present in an amount of about 0.5% by weight of the formulation on a free base basis. 
     
     
         51 . A pharmaceutical formulation according to  claim 1 , wherein said therapeutic agent is present in an amount of about 1% by weight of the formulation on a free base basis. 
     
     
         52 . A pharmaceutical formulation according to  claim 1 , wherein said therapeutic agent is present in an amount of about 1.5% by weight of the formulation on a free base basis. 
     
     
         53 . A pharmaceutical formulation according to  claim 1 , wherein said therapeutic agent is (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid salt. 
     
     
         54 - 74 . (canceled) 
     
     
         75 . A method of treating a skin disorder in a patient in need thereof, comprising applying a pharmaceutical formulation according to  claim 1  to an area of skin of said patient. 
     
     
         76 . (canceled) 
     
     
         77 . The method of  claim 75 , wherein the skin disorder is psoriasis. 
     
     
         78 - 82 . (canceled)

Join the waitlist — get patent alerts

Track US2015250790A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.